Vorasidenib Patent Expiration
Vorasidenib was first introduced by Servier Pharmaceuticals Llc
Vorasidenib Patents
Given below is the list of patents protecting Vorasidenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Voranigo | US11345677 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | Jan 16, 2039 | Servier |
| Voranigo | US11844758 | Therapeutically active compounds and their methods of use | Dec 04, 2035 | Servier |
| Voranigo | US10172864 | Therapeutically active compounds and their methods of use | Jul 11, 2034 | Servier |
| Voranigo | US12433895 | Therapeutically Active Compounds And Their Methods Of Use | Jul 11, 2034 | Servier |
| Voranigo | US9579324 | Therapeutically active compounds and their methods of use | Jul 11, 2034 | Servier |
Vorasidenib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vorasidenib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
